Loading…
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and rinzimetostat formerly known as ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study. It has a clinical trial collaboration and supply agreement with Bayer to evaluate ORIC-944 in combination with Nubeqa AR inhibitor; and a clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC 944 in combination with Erleada AR inhibitor. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-142M | $-129M | $-112M | -33.7% | - | 1.3% |
| 2024 | $0M | $-142M | $-128M | $-114M | -52.6% | - | 27.0% |
| 2023 | $0M | $-110M | $-101M | $-87M | -44.9% | - | 13.0% |
| 2022 | $0M | $-86M | $-89M | $-77M | -40.1% | - | - |
| 2021 | - | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 0 | 0 | 0 | 0 |
| Operating Revenue | - | 0 | 0 | 0 | 0 |
| Operating Expense | - | 86.77 | 110.78 | 142.90 | 143 |
| Research And Development | - | 61.68 | 85.17 | 114.07 | 109.82 |
| Selling General And Administration | - | 25.09 | 25.61 | 28.82 | 33.19 |
| Total Expenses | - | 86.77 | 110.78 | 142.90 | 143 |
| Operating Income | - | -86.77 | -110.78 | -142.90 | -143 |
| Total Operating Income As Reported | - | -91.77 | -110.78 | -142.90 | -143 |
| EBITDA | - | -85.80 | -109.75 | -141.79 | -141.78 |
| Normalized EBITDA | - | -80.80 | -109.75 | -141.79 | -141.78 |
| EBIT | - | -86.77 | -110.78 | -142.90 | -143 |
| Interest Income | 0.14 | 2.64 | - | - | - |
| Net Interest Income | 0.14 | 2.64 | - | - | - |
| Other Non Operating Income Expenses | - | 2.64 | 10.08 | 15.05 | 13.54 |
| Other Income Expense | - | -2.36 | 10.08 | 15.05 | 13.54 |
| Interest Income Non Operating | 0.14 | 2.64 | - | - | - |
| Net Non Operating Interest Income Expense | 0.14 | 2.64 | - | - | - |
| Pretax Income | - | -89.12 | -100.70 | -127.85 | -129.47 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | 0 | 0 |
| Net Income Continuous Operations | - | -89.12 | -100.70 | -127.85 | -129.47 |
| Net Income From Continuing And Discontinued Operation | - | -89.12 | -100.70 | -127.85 | -129.47 |
| Net Income From Continuing Operation Net Minority Interest | - | -89.12 | -100.70 | -127.85 | -129.47 |
| Net Income | - | -89.12 | -100.70 | -127.85 | -129.47 |
| Net Income Common Stockholders | - | -89.12 | -100.70 | -127.85 | -129.47 |
| Net Income Including Noncontrolling Interests | - | -89.12 | -100.70 | -127.85 | -129.47 |
| Normalized Income | - | -84.12 | -100.70 | -127.85 | -129.47 |
| Diluted NI Availto Com Stockholders | - | -89.12 | -100.70 | -127.85 | -129.47 |
| Basic Average Shares | 37.95 | 39.66 | 51.45 | 69.73 | - |
| Diluted Average Shares | 37.95 | 39.66 | 51.45 | 69.73 | - |
| Reconciled Depreciation | - | 0.97 | 1.03 | 1.11 | 1.22 |
| Total Unusual Items | 0 | -5 | 0 | - | - |
| Total Unusual Items Excluding Goodwill | 0 | -5 | 0 | - | - |
| Special Income Charges | 0 | -5 | 0 | - | - |
| Other Special Charges | - | 5 | - | - | - |
| General And Administrative Expense | - | 25.09 | 25.61 | 28.82 | 33.19 |
| Other Gand A | - | 25.09 | 25.61 | 28.82 | 33.19 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| ORIC Pharmaceuticals, Inc.this co. | ORIC | $830M | -6.41 | 2.16 | -33.7% | -5.56 |
| Arbutus Biopharma Corporation | ABUS | $859M | -25.65 | 11.22 | -43.7% | -25.48 |
| Theravance Biopharma, Inc. | TBPH | $844M | 7.97 | 2.84 | 35.7% | 5.34 |
| Janux Therapeutics, Inc. | JANX | $839M | -7.39 | 0.88 | -11.9% | -5.20 |
| LB Pharmaceuticals Inc | LBRX |
| - |
| - |
| - |
| - |
| $829M |
| -32.88 |
| 2.75 |
| -8.4% |
| -19.35 |
| Amphastar Pharmaceuticals, Inc. | AMPH | $825M | 8.41 | 1.05 | 12.4% | 6.17 |
| Sana Biotechnology, Inc. | SANA | $824M | -3.37 | 5.12 | -151.8% | -4.31 |
| Replimune Group, Inc. | REPL | $815M | -3.30 | 1.96 | -59.5% | -3.31 |
| Esperion Therapeutics, Inc. | ESPR | $806M | - | - | 7.5% | 13.94 |
| Peer Median | - | -3.37 | 2.75 | -10.1% | -3.81 | |